Fusion Antibodies plc
FAB.L · LSE
9/30/2025 | 3/31/2025 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £20 | £6 | £2 | £2 |
| - Cash | £0 | £0 | £0 | £1 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £20 | £6 | £2 | £1 |
| Revenue | £1 | £1 | £1 | £1 |
| % Growth | 10.6% | -37.2% | 102.9% | – |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 22.1% | 13.9% | 26.9% | -9.4% |
| EBITDA | -£0 | -£1 | -£1 | -£1 |
| % Margin | -56.8% | -117.2% | -61% | -129.9% |
| Net Income | -£1 | -£1 | -£1 | -£1 |
| % Margin | -61.1% | -126% | -62.8% | -146.1% |
| EPS Diluted | -0.005 | -0.01 | -0.014 | -0.017 |
| % Growth | 54.5% | 27.2% | 20% | – |
| Operating Cash Flow | -£1 | -£1 | -£1 | -£0 |
| Capital Expenditures | -£0 | -£0 | £0 | -£0 |
| Free Cash Flow | -£1 | -£1 | -£1 | -£0 |